GlassScriptPhysician profile
Gabriela M Blanco
NPI 1710186960
$2,701.33
in general payments reported to CMS, 2019-2025
21 companies · $645 in 2025
The $645 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $127 · 2021: $118 · 2022: $550 · 2023: $637 · 2024: $505 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $754.63 | 2019-2025 | Aklief, Oracea, Twyneo |
| Abbvie INC. | $419.78 | 2022-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $200.53 | 2022-2025 | |
| Amgen INC. | $198.71 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $159.87 | 2023-2025 | Dupixent |
| Acclarent, INC | $149.67 | 2022-2023 | Relieva Spinplus |
| Leo Pharma INC. | $132.67 | 2022-2025 | Adbry |
| Almirall LLC | $124.13 | 2019-2022 | |
| Genzyme Corporation | $103.08 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.46 | 2022-2024 | Arazlo, Cabtreo |
| Pfizer INC. | $47.98 | 2022-2025 | |
| Ucb, INC. | $44.72 | 2025 | Bimzelx |
| Journey Medical Corporation | $43.16 | 2025 | |
| Revance Therapeutics, INC. | $42.30 | 2025 | Daxxify |
| Organon LLC | $40.45 | 2025 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.08 | 2023 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $27.31 | 2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $23.60 | 2025 | |
| Arcutis Biotherapeutics, INC. | $23.54 | 2025 | Zoryve |
| Incyte Corporation | $22.99 | 2024 | Opzelura |
| Dermavant Sciences, INC. | $19.67 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriela Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.